CD19 and B-cell non-Hodgkin lymphoma: The only approach involving the CD137 receptor that has so far been approved by the FDA is the CAR-T cells therapy targeting the CD19 for the treatment of pediatric B-cell leukemia and refractory B-cell lymphoma [100].